Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME

 
• By Alaric DeArment

THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.

Eye
Oxurion announced that the Phase II study of THR-687 showed insufficient efficacy on its key endpoints • Source: Shutterstock

More from Strategy

More from Business